Self Study - Biologic Agents for Type 2 Inflammatory Diseases

Targeted biologic therapies are an important treatment for patients with type 2 inflammatory diseases. Pediatricians need to know which patients are candidates for these therapies and how to refer them to subspecialists for assessment and treatment.
Alan Baptist, MD, MPH

Division Chief of Allergy/Immunology in the Department of Internal Medicine
Henry Ford Health

Dr. Alan Baptist is a Professor and the Division Chief of Allergy/Immunology in the Department of Internal Medicine at Henry Ford Health. Dr Baptist completed his residency training in Internal Medicine as well as fellowship training in Allergy/Immunology at the University of Michigan. Dr Baptist also holds a joint appointment in the UM School of Public Health, and a Master of Public Health degree from Wayne State University. Dr Baptist has a particular interest in asthma. He has participated in numerous research studies, focusing on asthma education strategies, older adults with asthma, asthma health disparities and asthma guideline implementation. He has authored multiple publications and is the recipient of several research grant awards. He has previously served as the Fellowship Program Director for the Division of Allergy & Clinical Immunology.

1.
COMMUNICATE effectively with patients' families about the benefits of biologic treatments in managing Type 2 inflammatory conditions.